1352834-02-6

Basic information

• Product Name: C₇H₉NO
• Synonyms: C₇H₉NO
• CAS NO: 1352834-02-6
• Molecular Weight: 123.155
• Mol File: 1352834-02-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: C₇H₉NO(CAS DataBase Reference)
• NIST Chemistry Reference: C₇H₉NO(1352834-02-6)
• EPA Substance Registry System: C₇H₉NO(1352834-02-6)

Safety Data

• Hazardous Substances Data: 1352834-02-6(Hazardous Substances Data)

Upstream product

• 4771-80-6 1,2,5,6-tetrahydrobenzoic acid 
• 5709-98-8 (R)-cyclohex-3-enecarboxylic acid 

Downstream Products

• 1350636-90-6 N-(cyclohex-3-en-1(R)-yl)-2,2,2-trifluoro-acetamide 
• 1350636-87-1 (R)-(3-cyclohexenyl)carbamic acid tert-butyl ester 
• 1061337-51-6 14-O-{[(1R,2R,4R)-4-amino-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin 
• 1350636-89-3 {(1R,2R,4R)-4-[(tert-butoxycarbonyl)amino]-2-hydroxycyclohexyl}phenyl thioformate 
• 1350636-82-6 lefamulin acetate 
• 1350636-83-7 14-O-{[(1R,2R,4R)-4-amino-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin L-lactate 
• 1350636-84-8 14-O-{[(1R,2R,4R)-4-amino-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin hydrogenmaleate 
• 1350636-85-9 14-O-{[(1R,2R,4R)-4-ethoxycarbonylamino-2-hydroxy-cyclohexyl-sulfanyl]-acetyl}-mutilin 
• 1350636-75-7 [(1R,3R,4R)-3-hydroxy-4-mercaptocyclohexyl]carbamic acid tert-butyl ester 
• 40967-78-0 D-3-aminohexanedioic acid 

Relevant articles and documents

Facile access to chiral β-homoglutamic acid from 3-cyclohexene-carboxylic acid

A convenient, safe, and effective synthetic protocol for the synthesis of chiral β-homoglutamic acid was described. The strategy started from 3-cyclohexenecarboxylic acid, followed by three steps classic reaction including Curtius Rearrangement, oxidative

Pleuromutilin compounds for treating novel coronavirus pneumonia secondary bacterial infectious diseases

The present invention relates to novel pleuromutilin compounds, and a pharmaceutical composition and a use method thereof. Furthermore, the present invention also relates to a therapeutic method for treating bacterial infections, including infections caused by resistant microorganisms including multiple resistant microorganisms. The method and the compounds for treating secondary bacterial infectious diseases of novel coronavirus (COVID-19 or SARS-Cov-2) pneumonia, and the pharmaceutical composition of the compounds are especially provided, and provide scientific and technological support forwin-win new coronapneumonia epidemic prevention and control obstructing warfare.